ReiThera, a CDMO, has appointed Stefano Colloca as its Chief Executive Officer. Stefano brings decades of experience as a leader in viral vector technologies, having co-founded and directed numerous viral vector programs at Okairos Srl, before co-founding ReThera.

As CEO, Stefano will use his strategic insight and deep understanding of ReiThera and its novel vaccine platform to lead the company’s next growth phase and continue work in advancing gene therapy programs for vaccines and advanced therapies.

Stefano was one of the founders and the Director of Viral Vector Department at Okairos Srl. Previously, Stefano was Senior Research Fellow at IRBM, where he contributed to drug discovery programs on the hepatitis B and C viruses; and to the adenovirus vector development for therapeutic gene transfer and gene-based vaccination.

Stefano has strong research experience in the field of viral vectors for gene delivery and expertise in good manufacturing process (GMP) production and quality assessment. Stefano has overseen and directed manufacturing campaigns of numerous GMP clinical trial materials and is responsible for the GMP Facility at ReiThera.